B. Riley Wealth Advisors Inc. Lowers Holdings in Pfizer Inc. (NYSE:PFE)

B. Riley Wealth Advisors Inc. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 17.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 249,606 shares of the biopharmaceutical company's stock after selling 51,067 shares during the period. B. Riley Wealth Advisors Inc.'s holdings in Pfizer were worth $6,622,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Rialto Wealth Management LLC purchased a new position in Pfizer in the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. acquired a new position in Pfizer during the fourth quarter worth $27,000. Gould Capital LLC boosted its stake in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer during the fourth quarter worth $28,000. Finally, Noble Wealth Management PBC acquired a new position in Pfizer during the fourth quarter worth $31,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

PFE has been the topic of several recent analyst reports. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Cantor Fitzgerald initiated coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target on the stock. UBS Group upped their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Finally, Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Stock Up 1.2%

Shares of PFE traded up $0.29 during mid-day trading on Tuesday, reaching $23.61. The company's stock had a trading volume of 36,119,931 shares, compared to its average volume of 41,080,360. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The stock has a market cap of $134.23 billion, a PE ratio of 16.74, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company's 50 day moving average is $23.33 and its 200 day moving average is $25.13.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the prior year, the business posted $0.82 EPS. The business's revenue for the quarter was down 7.8% on a year-over-year basis. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.29%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.